Paris Business Products expands Dotz brand
WESTAMPTON, N.J. — A line of cord and cable management products is expanding to include a new item.
New Dotz reusable cord straps are designed to bundle together cords without having to use permanent ties. Each Dotz reusable cord strap features a built-in lock to keep bundles secure. The straps allow users to organize and uniquely identify cords by location and length.
Available in packs of five, new Dotz reusable cord straps carry a suggested retail price of $3.99.
Ready Pac Foods adds new organic salad offerings to lineup
IRWINDALE, Calif. — Ready Pac Foods has introduced new organic varieties to its popular Ready Pac Bistro bowl salad line.
Like the original product line, the new organic items are packaged in a convenient bowl, and include dressing and a fork, providing a simple solution for consumers to take the salad on the go. The new varieties include:
Organic orange ginger tofu is a vegan option with spring mix, pineapple, teriyaki tofu cubes, shredded carrots and shredded cabbage combined with orange ginger dressing;
Organic zesty harvest grains combines chopped romaine lettuce, shredded carrots and shredded cabbage with hearty golden quinoa, raisins, sliced almonds, garbanzo beans and zesty orange vinaigrette; and
Organic honey mustard spinach packs popular baby spinach, dried cranberries, sliced almonds, kidney beans and monterey jack cheese with honey mustard dressing.
"We are very excited to add new organic salads to our popular Ready Pac Bistro bowl salad line," Ready Pac director of marketing Tristan Simpson said. "Now shoppers of organic foods have healthy, convenient choices for brown bag lunches and meals on the run."
The suggested retail price for all varieties of Ready Pac Bistro organic bowl salads is $4.99 each.
Depomed sues FDA over drug for shingles-related pain
MENLO PARK, Calif. — A drug maker is suing the Food and Drug Administration to force the agency to give a special designation to one of its drugs.
Depomed announced that it had filed suit against the FDA in federal district court for the District of Columbia seeking an order that would require the agency to grant the drug Gralise (gabapentin) orphan drug exclusivity for the management of post-herpetic neuralgia. The disease, also known as PHN, is a condition causing prolonged pain in people who have had shingles, a complication of chickenpox.
The FDA granted Gralise orphan drug designation for management of PHN in November 2010 and approved the drug in January 2011, but it has not granted it orphan drug exclusivity. Under FDA regulations, orphan drug designation is given to drugs for diseases that affect fewer than 200,000 people in the United States, and drugs that receive the designation are entitled to seven years’ market exclusivity, as opposed to the five years given to other drugs.